This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

BioProcess International US West
Mark Your Calendar for BPI US West 2024!
March 11-14, 2024Town and Country Resort, San Diego

Ying Shen
Associate Scientific Fellow at Takeda Pharmaceuticals Co Ltd.


Evaluation of sequence variants by NGS has been incorporated into Cell Line Development (CLD) process for protein biologics and retroviral vectors. As a clone selection and quality control step, an in-house Illumina MiSeq platform is used to eliminate clones that showed sequence variants in GOI. In addition, NGS was also tested for potential adventitious pathogens detection.

Agenda Sessions

  • NextGen Sequencing (NGS) platform and applications in cell line development